CORD BLOOD CLINICAL TRIAL RECEIVES FDA AUTHORIZATION
Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products:
Minimal Manipulation and Homologous Use
FDA Issues Extension period to May 31, 2021 for minimal manipulation products.
Maximum Signaling for Maximum Regeneration
RichSource Announces Non-Invasive Breakthrough Product RICHGEN
